Tanvex BioPharma, Inc.

Equities

6541

KYG8676P1037

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
39.2 ^TWD	+1.29%		+3.16%	-39.78%

05-28	Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index	CI
05-13	Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tanvex Biopharma, Inc. Announces Position Adjustment of Acting Spokesperson and Corporate Governance Officer from Jerry Yu to Stacey Tsai

February 20, 2023 at 05:36 am

Tanvex BioPharma, Inc. announced position adjustment of acting spokesperson and corporate governance officer from Jerry Yu to Stacey Tsai (Senior Director of Accounting) with effect from February 20, 2023.

Latest news about Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index	05-27	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-12	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	02-06	CI
Tanvex BioPharma, Inc. Announces the Appointment of Chen, Lin-Cheng as CEO	02-06	CI
Tanvex Biologics Corporation announced that it expects to receive $5 million in funding from Tanvex BioPharma, Inc.	02-05	CI
Tanvex BioPharma USA, Inc. announced that it expects to receive $50 million in funding from Tanvex BioPharma, Inc.	02-05	CI
Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer	01-05	CI
Tanvex BioPharma, Inc. Announces Change of Chairman	12-29	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen Chairperson and Director, Effective December 29, 2023	12-21	CI
Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer	12-21	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as CEO, Effective December 29, 2023	12-21	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023	12-21	CI
Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer	11-30	CI
Tanvex BioPharma, Inc. Appoints Wen Chung Yeh as Chief Financial Officer	11-13	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-12	CI
Tanvex BioPharma, Inc. Announces Management Changes	11-01	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to S&P Global BMI Index	23-09-17	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index	23-09-07	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from Taiwan TAIEX Index	23-04-12	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index	23-03-20	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI

Chart Tanvex BioPharma, Inc.

Duration

Period

More charts

Company Profile

Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

More about the company

	1st Jan change	Capi.
TANVEX BIOPHARMA, INC.	-39.78%	198M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs